Case 1:20-cv-00690-TJM-CFH Document 24 Filed 07/28/20 Page 1 of 3
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF NEW YORK
`
`
`
`
`NOVARTIS PHARMA AG, NOVARTIS
`PHARMACEUTICALS CORPORATION, and
`NOVARTIS TECHNOLOGY LLC,
`
`
`Plaintiffs,
`
`
`
`
`
`Civil Action No.: 1:20-cv-00690 (TJM-CFH)
`
`
`JURY TRIAL DEMANDED
`
`
`
`
`v.
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`Defendant.
`
`
`
`UNOPPOSED MOTION TO STAY PURSUANT TO 28 U.S.C. § 1659
`
`Defendant Regeneron Pharmaceuticals, Inc. (“Regeneron”) hereby respectfully moves to
`
`stay the above-captioned case pursuant to 28 U.S.C. § 1659.1 Plaintiffs Novartis Pharma AG,
`
`Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, “Novartis”)
`
`do not oppose this motion. Support for this motion is found in the accompanying Memorandum of
`
`Law and Affidavit of Anish Desai.
`
`
`1
`By virtue of this motion, Regeneron does not waive, and in fact, expressly reserves, all
`defenses and procedural rights otherwise available to it.
`
`Novartis Exhibit 2042.001
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24 Filed 07/28/20 Page 2 of 3
`
`Dated: July 28, 2020
`
`
`/s/ Anish Desai
`Elizabeth Weiswasser (Bar Roll No.
`701918)
`Anish Desai (Bar Roll No. 701945)
`WEIL, GOTSHAL & MANGES LLP
`767 Fifth Avenue
`New York, New York 10153-011
`Telephone: (212) 310-8000
`Fax: (212) 310-8007
`anish.desai@weil.com
`elizabeth.weiswasser@weil.com
`
`Brian Ferguson (Bar Roll No. 701958)
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street, NW
`Washington, D.C. 20036
`Telephone: (202) 682-7000
`Fax: (202) 857-0940
`brian.ferguson@weil.com
`
`Counsel for Defendant Regeneron
`Pharmaceuticals, Inc.
`
`Dated: __________, 2020
`
`
`
`SO ORDERED:
`
`
`__________________________________
`Honorable Thomas J. McAvoy, U.S.D.J.
`
`2
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2042.002
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24 Filed 07/28/20 Page 3 of 3
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF NEW YORK
`
`
`
`NOVARTIS PHARMA AG, NOVARTIS
`PHARMACEUTICALS CORPORATION, and
`NOVARTIS TECHNOLOGY LLC,
`
`
`Plaintiffs,
`
`
`
`v.
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`Defendant.
`
`
`
`Civil Action No.: 1:20-cv-00690 (TJM-CFH)
`
`
`JURY TRIAL DEMANDED
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`I hereby certify that on July 28, 2020, I electronically filed the foregoing UNOPPOSED
`
`MOTION TO STAY PURSUANT TO 28 U.S.C. § 1659 with the Clerk of the District Court
`
`using the CM/ECF system, which sent notification of such filing upon the counsel of record.
`
`
`
`Dated: July 28, 2020
`
`
`
`
`/s/ Anish R. Desai
`Anish R. Desai
`
`
`
`
`Novartis Exhibit 2042.003
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-1 Filed 07/28/20 Page 1 of 3
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF NEW YORK
`
`
`
`
`NOVARTIS PHARMA AG, NOVARTIS
`PHARMACEUTICALS CORPORATION, and
`NOVARTIS TECHNOLOGY LLC,
`
`
`Plaintiffs,
`
`
`
`
`
`Civil Action No.: 1:20-cv-00690 (TJM-CFH)
`
`
`JURY TRIAL DEMANDED
`
`
`
`
`v.
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`Defendant.
`
`
`
`MEMORANDUM OF LAW IN SUPPORT OF UNOPPOSED MOTION TO STAY
`PURSUANT TO 28 U.S.C. § 1659
`
`For the reasons stated below, the Court should grant the motion to stay the above-captioned
`
`matter pursuant to 28 U.S.C. § 1659. Plaintiffs Novartis Pharma AG, Novartis Pharmaceuticals
`
`Corporation, and Novartis Technology LLC (collectively, “Novartis”) filed this action against
`
`Defendant Regeneron Pharmaceuticals, Inc. (“Regeneron”) on June 19, 2020, alleging
`
`infringement solely of U.S. Patent No. 9,220,631 (“the ’631 patent”). Also on June 19, 2020,
`
`Novartis filed a Complaint in the U.S. International Trade Commission (“ITC”), requesting that
`
`the ITC institute an investigation against Regeneron under Section 337 of the Tariff Act of 1930,
`
`as amended. In the ITC complaint, Novartis asserted infringement against Regeneron of the same
`
`’631 patent that is at issue in this case.
`
`On July 21, 2020, the ITC issued a notice of institution of the investigation, entitled
`
`Certain Pre-filled Syringes for Intravitreal Injection and Components Thereof, Investigation No.
`
`337-TA-1207 (“ITC Proceeding”). Pursuant to 19 C.F.R. § 210.10(b), the investigation was
`
`Novartis Exhibit 2042.004
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-1 Filed 07/28/20 Page 2 of 3
`
`instituted by publication of the Notice of Institution in the Federal Register on July 27, 2020.
`
`Exhibit A, Federal Register, Vol. 85, No. 144 at 45,227-45,228. Under Section 1659 of Title 28,
`
`upon the request of any party to a civil action that is also a respondent in an ITC proceeding
`
`involving the parties in the civil action, the Court “shall stay, until the determination of the
`
`Commission becomes final, proceedings in the civil action with respect to any claim that involves
`
`the same issues involved in the proceeding before the Commission.” 28 U.S.C. § 1659(a). The stay
`
`is mandatory and must be granted if it is made within thirty days from the later of: (1) the party
`
`being named a respondent in a proceeding before the ITC, or (2) the filing of the district court
`
`action. 28 U.S.C. § 1659(a)(1)-(2); see also In re Princo, 478 F.3d 1345, 1355 (Fed. Cir. 2007)
`
`(granting writ of mandamus and directing district court to stay proceedings pursuant to 28 U.S.C.
`
`§ 1659(a) until the ITC proceeding became final and was no longer subject to judicial review).
`
`Here, the ITC Proceeding involves the same Defendant as this civil action. See Exhibit A,
`
`Federal Register, Vol. 85, No. 144 at 45,228. Novartis alleges infringement of only the ’631 patent
`
`in both the ITC Proceeding and this civil action. Id. As this action involves the same issues as the
`
`ITC Proceeding, a stay of this action is required pursuant to 28 U.S.C. § 1659(a). The ITC issued
`
`a Notice of Institution of Investigation on July 21, 2020, which was published in the Federal
`
`Register on July 27, 2020. Therefore, this motion is timely filed within thirty days of Regeneron
`
`being named as a respondent in the ITC Proceeding. Finally, Novartis does not oppose this motion.
`
`For the foregoing reasons, Regeneron respectfully requests that the Court stay this action
`
`under 28 U.S.C. § 1659(a) until determination of the ITC Proceeding, including any appeals
`
`therefrom, becomes final.
`
`
`
`
`
`2
`
`Novartis Exhibit 2042.005
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-1 Filed 07/28/20 Page 3 of 3
`
`Dated: July 28, 2020
`
`
`
`
`
`
`/s/ Anish Desai
`Elizabeth Weiswasser (Bar Roll No.
`701918)
`Anish Desai (Bar Roll No. 701945)
`WEIL, GOTSHAL & MANGES LLP
`767 Fifth Avenue
`New York, New York 10153-011
`Telephone: (212) 310-8000
`Fax: (212) 310-8007
`anish.desai@weil.com
`elizabeth.weiswasser@weil.com
`
`Brian Ferguson (Bar Roll No. 701958)
`WEIL, GOTSHAL & MANGES LLP
`2001 M Street, NW
`Washington, D.C. 20036
`Telephone: (202) 682-7000
`Fax: (202) 857-0940
`brian.ferguson@weil.com
`
`Counsel for Defendant Regeneron
`Pharmaceuticals, Inc.
`
`3
`
`Novartis Exhibit 2042.006
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-2 Filed 07/28/20 Page 1 of 2
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE NORTHERN DISTRICT OF NEW YORK
`
`
`
`
`NOVARTIS PHARMA AG, NOVARTIS
`PHARMACEUTICALS CORPORATION, and
`NOVARTIS TECHNOLOGY LLC,
`
`
`Plaintiffs,
`
`
`
`
`
`Civil Action No.: 1:20-cv-00690 (TJM-CFH)
`
`
`JURY TRIAL DEMANDED
`
`
`
`
`v.
`
`
`REGENERON PHARMACEUTICALS, INC.,
`
`
`Defendant.
`
`
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`AFFIDAVIT IN SUPPORT OF UNOPPOSED MOTION TO STAY PURSUANT
`TO 28 U.S.C. § 1659
`
`Anish Desai, being duly sworn, deposes and says:
`
`I am an attorney at Weil, Gotshal & Manges LLP, counsel for Defendant Regeneron
`Pharmaceuticals, Inc. (“Regeneron”).
`
`I am a member in good standing of the state bar of New York, the U.S. District Court for
`the Northern District of New York, the U.S. Court of Appeals for the District of Columbia,
`the U.S. Court of Appeals for the Federal Circuit, the U.S. District Court for the Eastern
`District of Texas, and the United States Patent and Trademark Office.
`
`I submit this affidavit in support of the Motion to Stay Pursuant to 28 U.S.C. § 1659.
`
`Plaintiffs Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis
`Technology LLC (collectively, “Novartis”) filed this action against Defendant Regeneron
`Pharmaceuticals, Inc. (“Regeneron”) on June 19, 2020, alleging infringement solely of U.S.
`Patent No. 9,220,631 (“the ’631 patent”).
`
`Also on June 19, 2020, Novartis filed a Complaint in the U.S. International Trade
`Commission (“ITC”), requesting that the ITC institute an investigation against Regeneron
`under Section 337 of the Tariff Act of 1930, as amended.
`
`In the ITC complaint, Novartis asserted infringement against Regeneron of the same ’631
`patent that is at issue in this case.
`
`Novartis Exhibit 2042.007
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-2 Filed 07/28/20 Page 2 of 2
`
`7.
`
`8.
`
`9.
`
`10.
`
`11.
`
`12.
`
`On July 21, 2020, the ITC issued a Notice of Institution of Investigation Re Certain Pre-
`filled Syringes for Intravitreal Injection and Components Thereof, Investigation No. 337-
`TA-1207 (“ITC Proceeding”).
`
`Pursuant to 19 C.F.R. § 210.10(b), the ITC Proceeding was instituted by publication of the
`Notice of Institution in the Federal Register on July 27, 2020. Exhibit A, Federal Register,
`Vol. 85, No. 144 at 45,227-45,228.
`
`The ITC Proceeding involves the same Defendant as this civil action. See id. at 45,228.
`
`Novartis alleges infringement of only the ’631 patent in both the ITC Proceeding and this
`civil action. Id.
`
`This motion is filed within thirty days of Regeneron being named as a respondent in the
`ITC Proceeding.
`
`Counsel for Regeneron communicated with Novartis’s counsel regarding the relief
`requested herein. Novartis stated that it does not oppose this motion.
`
`I, Anish Desai, declare under penalty of perjury that the foregoing is true and correct.
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: July 28, 2020
`
`
`/s/ Anish Desai
`Anish Desai (Bar Roll No. 701945)
`
`2
`
`Novartis Exhibit 2042.008
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-3 Filed 07/28/20 Page 1 of 3
`
`EXHIBIT A
`
`Novartis Exhibit 2042.009
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-3 Filed 07/28/20 Page 2 of 3
`
`Federal Register / Vol. 85, No. 144 / Monday, July 27, 2020 / Notices
`
`45227
`
`United States, or United States
`consumers.
`In particular, the Commission is
`interested in comments that:
`(i) Explain how the articles
`potentially subject to the requested
`remedial orders are used in the United
`States;
`(ii) identify any public health, safety,
`or welfare concerns in the United States
`relating to the requested remedial
`orders;
`(iii) identify like or directly
`competitive articles that complainant,
`its licensees, or third parties make in the
`United States which could replace the
`subject articles if they were to be
`excluded;
`(iv) indicate whether complainant,
`complainant’s licensees, and/or third
`party suppliers have the capacity to
`replace the volume of articles
`potentially subject to the requested
`exclusion order and/or a cease and
`desist order within a commercially
`reasonable time; and
`(v) explain how the requested
`remedial orders would impact United
`States consumers.
`Written submissions on the public
`interest must be filed no later than by
`close of business, eight calendar days
`after the date of publication of this
`notice in the Federal Register. There
`will be further opportunities for
`comment on the public interest after the
`issuance of any final initial
`determination in this investigation. Any
`written submissions on other issues
`must also be filed by no later than the
`close of business, eight calendar days
`after publication of this notice in the
`Federal Register. Complainant may file
`replies to any written submissions no
`later than three calendar days after the
`date on which any initial submissions
`were due. Any submissions and replies
`filed in response to this Notice are
`limited to five (5) pages in length,
`inclusive of attachments.
`Persons filing written submissions
`must file the original document
`electronically on or before the deadlines
`stated above. Submissions should refer
`to the docket number (‘‘Docket No.
`3475’’) in a prominent place on the
`cover page and/or the first page. (See
`Handbook for Electronic Filing
`Procedures, Electronic Filing
`Procedures 1). Please note the
`Secretary’s Office will accept only
`electronic filings during this time.
`Filings must be made through the
`Commission’s Electronic Document
`Information System (EDIS, https://
`
`edis.usitc.gov.) No in-person paper-
`based filings or paper copies of any
`electronic filings will be accepted until
`further notice. Persons with questions
`regarding filing should contact the
`Secretary at EDIS3Help@usitc.gov.
`Any person desiring to submit a
`document to the Commission in
`confidence must request confidential
`treatment. All such requests should be
`directed to the Secretary to the
`Commission and must include a full
`statement of the reasons why the
`Commission should grant such
`treatment. See 19 CFR 201.6. Documents
`for which confidential treatment by the
`Commission is properly sought will be
`treated accordingly. All information,
`including confidential business
`information and documents for which
`confidential treatment is properly
`sought, submitted to the Commission for
`purposes of this Investigation may be
`disclosed to and used: (i) By the
`Commission, its employees and Offices,
`and contract personnel (a) for
`developing or maintaining the records
`of this or a related proceeding, or (b) in
`internal investigations, audits, reviews,
`and evaluations relating to the
`programs, personnel, and operations of
`the Commission including under 5
`U.S.C. Appendix 3; or (ii) by U.S.
`government employees and contract
`personnel 2, solely for cybersecurity
`purposes. All nonconfidential written
`submissions will be available for public
`inspection at the Office of the Secretary
`and on EDIS.3
`This action is taken under the
`authority of section 337 of the Tariff Act
`of 1930, as amended (19 U.S.C. 1337),
`and of §§ 201.10 and 210.8(c) of the
`Commission’s Rules of Practice and
`Procedure (19 CFR 201.10, 210.8(c)).
`By order of the Commission.
`Issued: July 22, 2020.
`Lisa Barton,
`Secretary to the Commission.
`[FR Doc. 2020–16238 Filed 7–24–20; 8:45 am]
`BILLING CODE 7020–02–P
`
`INTERNATIONAL TRADE
`COMMISSION
`
`[Investigation No. 337–TA–1207]
`
`Certain Pre-Filled Syringes for
`Intravitreal Injection and Components
`Thereof; Institution of Investigation
`AGENCY: U.S. International Trade
`Commission.
`
`1 Handbook for Electronic Filing Procedures:
`https://www.usitc.gov/documents/handbook_on_
`filing_procedures.pdf.
`
`2 All contract personnel will sign appropriate
`nondisclosure agreements.
`3 Electronic Document Information System
`(EDIS): https://edis.usitc.gov.
`
`ACTION: Notice.
`SUMMARY: Notice is hereby given that a
`complaint was filed with the U.S.
`International Trade Commission on June
`19, 2020, under section 337 of the Tariff
`Act of 1930, as amended, on behalf of
`Novartis Pharma AG of Switzerland;
`Novartis Pharmaceuticals Corporation of
`East Hanover, New Jersey; and Novartis
`Technology LLC of East Hanover, New
`Jersey. A letter supplementing the
`complaint was filed on July 10, 2020.
`The complaint alleges violations of
`section 337 based upon the importation
`into the United States, the sale for
`importation, and the sale within the
`United States after importation of
`certain pre-filled syringes for
`intravitreal injection and components
`thereof by reason of infringement of
`certain claims of U.S. Patent No.
`9,220,631 (‘‘the ’631 patent’’). The
`complaint further alleges that an
`industry in the United States exists or
`is in the process of being established as
`required by the applicable Federal
`Statute. The complainants request that
`the Commission institute an
`investigation and, after the
`investigation, issue a limited exclusion
`order and a cease and desist order.
`ADDRESSES: The complaint, except for
`any confidential information contained
`therein, may be viewed on the
`Commission’s electronic docket (EDIS)
`at https://edis.usitc.gov. For help
`accessing EDIS, please email
`EDIS3Help@usitc.gov. Hearing impaired
`individuals are advised that information
`on this matter can be obtained by
`contacting the Commission’s TDD
`terminal on (202) 205–1810. Persons
`with mobility impairments who will
`need special assistance in gaining access
`to the Commission should contact the
`Office of the Secretary at (202) 205–
`2000. General information concerning
`the Commission may also be obtained
`by accessing its internet server at
`https://www.usitc.gov.
`FOR FURTHER INFORMATION CONTACT:
`Pathenia M. Proctor, The Office of
`Unfair Import Investigations, U.S.
`International Trade Commission,
`telephone (202) 205–2560.
`SUPPLEMENTARY INFORMATION:
`Authority: The authority for institution of
`this investigation is contained in section 337
`of the Tariff Act of 1930, as amended, 19
`U.S.C. 1337, and in § 210.10 of the
`Commission’s Rules of Practice and
`Procedure, 19 CFR 210.10 (2020).
`Scope of Investigation: Having
`considered the complaint, the U.S.
`International Trade Commission, on
`July 21, 2020, 2020, ordered that—
`(1) Pursuant to subsection (b) of
`section 337 of the Tariff Act of 1930, as
`
`VerDate Sep<11>2014 19:31 Jul 24, 2020 Jkt 250001 PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\27JYN1.SGM 27JYN1
`
`jbell on DSKJLSW7X2PROD with NOTICES
`
`Novartis Exhibit 2042.010
`Regeneron v. Novartis, IPR2020-01318
`
`

`

`Case 1:20-cv-00690-TJM-CFH Document 24-3 Filed 07/28/20 Page 3 of 3
`
`45228
`
`Federal Register / Vol. 85, No. 144 / Monday, July 27, 2020 / Notices
`
`amended, an investigation be instituted
`to determine whether there is a
`violation of subsection (a)(1)(B) of
`section 337 in the importation into the
`United States, the sale for importation,
`or the sale within the United States after
`importation of certain products
`identified in paragraph (2) by reason of
`infringement of one or more of claims
`1–6 and 11–26 of the ’631 patent, and
`whether an industry in the United
`States exists as required by subsection
`(a)(2) of section 337;
`(2) Pursuant to § 210.10(b)(1) of the
`Commission’s Rules of Practice and
`Procedure, 19 CFR 210.10(b)(1), the
`plain language description of the
`accused products or category of accused
`products, which defines the scope of the
`investigation, is ‘‘syringes that are pre-
`filled with ophthalmic medication, and
`components of such syringes, including
`barrels, plungers, and stoppers’’;
`(3) Pursuant to Commission Rule
`§ 210.50(b)(1), 19 CFR 210.50(b)(1), the
`presiding administrative law judge shall
`take evidence or other information and
`hear arguments from the parties or other
`interested persons with respect to the
`public interest in this investigation, as
`appropriate, and provide the
`Commission with findings of fact and a
`recommended determination on this
`issue, which shall be limited to the
`statutory public interest factors set forth
`in 19 U.S.C. 1337(d)(1), (f)(1), (g)(1);
`(4) For the purpose of the
`investigation so instituted, the following
`are hereby named as parties upon which
`this notice of investigation shall be
`served:
`(a) The complainants are:
`Novartis Pharma AG, Forum 1, Novartis
`Campus, CH–4056 Basel, Switzerland.
`Novartis Pharmaceuticals Corporation,
`One Health Plaza, East Hanover, New
`Jersey, 07936.
`Novartis Technology LLC, One Health
`Plaza, East Hanover, New Jersey,
`07936.
`(b) The respondent is the following
`entity alleged to be in violation of
`section 337, and is the party upon
`which the complaint is to be served:
`Regeneron Pharmaceuticals, Inc., 77 Old
`Saw Mill River Road, Tarrytown, New
`York 10591.
`(c) The Office of Unfair Import
`Investigations, U.S. International Trade
`Commission, 500 E Street SW, Suite
`401, Washington, DC 20436; and
`(5) For the investigation so instituted,
`the Chief Administrative Law Judge,
`U.S. International Trade Commission,
`shall designate the presiding
`Administrative Law Judge.
`Responses to the complaint and the
`notice of investigation must be
`
`submitted by the named respondent in
`accordance with § 210.13 of the
`Commission’s Rules of Practice and
`Procedure, 19 CFR 210.13. Pursuant to
`19 CFR 201.16(e) and 210.13(a), as
`amended in 85 FR 15798 (March 19,
`2020), such responses will be
`considered by the Commission if
`received not later than 20 days after the
`date of service by the complainants of
`the complaint and the notice of
`investigation. Extensions of time for
`submitting responses to the complaint
`and the notice of investigation will not
`be granted unless good cause therefor is
`shown.
`Failure of the respondent to file a
`timely response to each allegation in the
`complaint and in this notice may be
`deemed to constitute a waiver of the
`right to appear and contest the
`allegations of the complaint and this
`notice, and to authorize the
`administrative law judge and the
`Commission, without further notice to
`the respondent, to find the facts to be as
`alleged in the complaint and this notice
`and to enter an initial determination
`and a final determination containing
`such findings, and may result in the
`issuance of an exclusion order or a cease
`and desist order or both directed against
`the respondent.
`By order of the Commission.
`Issued: July 21, 2020.
`Lisa Barton,
`Secretary to the Commission.
`[FR Doc. 2020–16138 Filed 7–24–20; 8:45 am]
`BILLING CODE 7020–02–P
`
`industry in the United States within a
`reasonably foreseeable time.
`Background
`The Commission instituted these
`reviews on May 1, 2019 (84 FR 18577)
`and determined on August 5, 2019 that
`it would conduct full reviews (84 FR
`44330, August 23, 2019). Notice of the
`scheduling of the Commission’s reviews
`and of a public hearing to be held in
`connection therewith was given by
`posting copies of the notice in the Office
`of the Secretary, U.S. International
`Trade Commission, Washington, DC,
`and by publishing the notice in the
`Federal Register on January 22, 2020
`(85 FR 3717). Subsequently, the
`Commission cancelled its previously
`scheduled hearing following a request
`on behalf of the domestic interested
`parties (85 FR 31550, May 26, 2020).
`The Commission made these
`determinations pursuant to section
`751(c) of the Act (19 U.S.C. 1675(c)). It
`completed and filed its determinations
`in these reviews on July 22, 2020. The
`views of the Commission are contained
`in USITC Publication 5086 (July 2020),
`entitled Light-Walled Rectangular Pipe
`and Tube from China, Korea, Mexico,
`and Turkey: Investigation Nos. 701–TA–
`449 and 731–TA–1118–1121 (Second
`Review).
`By order of the Commission.
`Issued: July 22, 2020.
`Lisa Barton,
`Secretary to the Commission.
`[FR Doc. 2020–16236 Filed 7–24–20; 8:45 am]
`BILLING CODE 7020–02–P
`
`INTERNATIONAL TRADE
`COMMISSION
`
`[Investigation Nos. 701–TA–449 and 731–
`TA–1118–1121 (Second Review)]
`
`Light-Walled Rectangular Pipe and
`Tube From China, Korea, Mexico, and
`Turkey
`
`Determination
`On the basis of the record 1 developed
`in the subject five-year reviews, the
`United States International Trade
`Commission (‘‘Commission’’)
`determines, pursuant to the Tariff Act of
`1930 (‘‘the Act’’), that revocation of the
`countervailing duty order on light-
`walled rectangular pipe and tube from
`China and antidumping duty orders on
`light-walled rectangular pipe and tube
`from China, Korea, Mexico, and Turkey
`would be likely to lead to continuation
`or recurrence of material injury to an
`
`1 The record is defined in sec. 207.2(f) of the
`Commission’s Rules of Practice and Procedure (19
`CFR 207.2(f)).
`
`DEPARTMENT OF JUSTICE
`
`Bureau of Alcohol, Tobacco, Firearms
`and Explosives
`[OMB Number 1140–0013]
`
`Agency Information Collection
`Activities; Proposed eCollection
`eComments Requested; Application
`for Tax-Exempt Transfer of Firearm
`and Registration to Special
`Occupational Taxpayer—ATF Form 3
`(5320.3)
`AGENCY: Bureau of Alcohol, Tobacco,
`Firearms and Explosives, Department of
`Justice.
`ACTION: 30-Day notice.
`SUMMARY: The Department of Justice
`(DOJ), Bureau of Alcohol, Tobacco,
`Firearms and Explosives (ATF), will
`submit the following information
`collection request to the Office of
`Management and Budget (OMB) for
`review and approval in accordance with
`the Paperwork Reduction Act of 1995.
`
`VerDate Sep<11>2014 19:31 Jul 24, 2020 Jkt 250001 PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 E:\FR\FM\27JYN1.SGM 27JYN1
`
`jbell on DSKJLSW7X2PROD with NOTICES
`
`Novartis Exhibit 2042.011
`Regeneron v. Novartis, IPR2020-01318
`
`